IPCA Laboratories Limited

10%

mation given during the call. Domestic formulation business for the quarter [inaudible 00:01:53] 10% growth, and domestic antimalarial business has shown a decline of almost, around 19% for the quart

19%

ble 00:01:53] 10% growth, and domestic antimalarial business has shown a decline of almost, around 19% for the quarter. IPCA is second fastest growing in IPM among the top 20 players in mid-September 2

1.86%

stabilizing now, and we will see much better results in future. Our market share has improved to 1.86% in last 4 years from 1.59% in 2018 and for Q2 FY23, our market share has further improved to aroun

1.59%

ll see much better results in future. Our market share has improved to 1.86% in last 4 years from 1.59% in 2018 and for Q2 FY23, our market share has further improved to around 1.91% overall of the phar

1.91%

n last 4 years from 1.59% in 2018 and for Q2 FY23, our market share has further improved to around 1.91% overall of the pharmaceutical market. Our export promotional business has delivered a growth of al

33%

the pharmaceutical market. Our export promotional business has delivered a growth of almost around 33% for the quarter. Export generic business, including institutional, has delivered almost around 8%

8%

33% for the quarter. Export generic business, including institutional, has delivered almost around 8% growth for the Transcript – IPCA Laboratories Q2 FY23 Earnings Call - 2 -

12%

Call - 2 - quarter. Institutional business per se, has delivered around 12% growth and generics has delivered around 4% growth for the quarter. Our active pharmaceutical busi

4%

. Institutional business per se, has delivered around 12% growth and generics has delivered around 4% growth for the quarter. Our active pharmaceutical business has declined by around 15% for the quar

15%

ivered around 4% growth for the quarter. Our active pharmaceutical business has declined by around 15% for the quarter, mainly due to the lower demand in Latin America and Asia and pricing pressures wi

2%

iness. Our overall, for the year, API business is expected to deliver a negative growth of around 2% for the whole of the financial year 2023. Material cost to income is at around 32.83% for Q2 FY23

32.83%

growth of around 2% for the whole of the financial year 2023. Material cost to income is at around 32.83% for Q2 FY23 as against 33.09 for the same period last year. There is an improvement of around 0.26